Skip to content
Bored Studies
RecruitingPhase 2

Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis

Enveda Therapeutics · NCT07298395

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–75 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 2
Target enrollment
105
US sites recruiting
32
Study start
December 22, 2025
Record last updated
September 25, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

The goal of this clinical trial is to learn about the safety and effectiveness of ENV-294 in adults with moderate to severe atopic dermatitis.

The main questions it will answer are

  • Is there an impact on the severity and area of atopic dermatitis when participants take ENV-294
  • What medical problems do participants have when taking ENV-294

Participants will

  • Take drug ENV-294 or a placebo once every day for 12 weeks
  • Visit the clinic every 2 to 4 weeks for checkups and tests
  • Keep a diary of their symptoms and when they took their study drug
  • Return to the clinic for the final study visit at approximately week 16

Being studied: ENV-294; Placebo

Conditions: Atopic Dermatitis (AD)

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Have chronic atopic dermatitis that was diagnosed at least 12 months prior to the first study visit
  • Have moderate-to-severe AD at screening and baseline as defined by the following criteria:
  • A vIGA score of 3 (moderate) or 4 (severe)
  • EASI score of ≥16
  • BSA ≥10%
  • PP-NRS score of ≥4
  • Have had either a poor response or intolerance to topical treatments for atopic dermatitis (such as corticosteroids) within the past 6 months
  • Use a bland moisturizer at least daily

Exclusion Criteria

  • Current or recurrent medical conditions that could affect the study drug or study assessments
  • Any illness that could impact participant safety or active infections
  • Ongoing skin condition or large tattoos that would interfere with clinical assessment
  • Clinically significant skin infection requiring treatment
  • Clinically significant abnormal laboratory assessments at screening

Recruiting US locations

Study contacts (from the official record)

  • Clinical Operations · env-294.clinicaltrials@enveda.com
All dermatology studies in Alabama →
Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis (NCT07298395) | Bored Studies